GlassScriptPhysician profile
Andrew Dodson Beaty
NPI 1891848271
$11,960.14
in general payments reported to CMS, 2019-2025
32 companies · $2,833 in 2025
The $2,833 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $679 · 2021: $425 · 2022: $891 · 2023: $2,330 · 2024: $2,798 · 2025: $2,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,800 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,800.47 |
| Education | $159.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,657.10 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,451.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,400.36 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,238.41 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $784.42 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $709.76 | 2019-2025 | Haegarda, Hizentra, Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $581.48 | 2020-2025 | Takhzyro, Cuvitru |
| Blueprint Medicines Corporation | $573.00 | 2023-2025 | Ayvakit |
| Pfizer INC. | $558.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $544.36 | 2019-2025 | |
| Genentech USA, INC. | $299.86 | 2019-2024 | Xolair |
| Pharming Healthcare, INC. | $233.84 | 2019-2025 | Ruconest |
| Galderma Laboratories, L.P. | $202.83 | 2025 | Nemluvio |
| Kaleo, INC. | $202.03 | 2023 | Auvi-Q |
| Covis Pharma Gmbh | $154.77 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $147.21 | 2022 | |
| Biocryst US Sales Co., LLC | $132.49 | 2024-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $127.36 | 2022-2023 | |
| Sanofi US Services INC. | $122.74 | 2025 | |
| Amgen INC. | $120.63 | 2019-2025 | Tezspire |
| Shire North American Group INC | $119.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $104.53 | 2019-2022 | |
| Abbvie INC. | $101.63 | 2022-2023 | Rinvoq |
| Ars Pharmaceuticals Operations, INC. | $91.18 | 2025 | Neffy |
| Optinose US, INC. | $68.85 | 2023-2024 | |
| Incyte Corporation | $44.03 | 2023 | Opzelura |
| Alk-Abello, INC | $43.53 | 2020-2023 | Ragwitek, Odactra, Grastek |
| Organon LLC | $43.11 | 2025 | Vtama |
| Lilly USA, LLC | $35.72 | 2024-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $28.19 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $23.22 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $13.75 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Beaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.